China-based Jiangxi Jemincare Group has entered into a licensing agreement with Swiss giant Roche’s Genentech. The deal grants Genentech exclusive global development and commercialization rights to Jemincare’s oral androgen receptor (AR) degrader, JMKX00299, including all related intellectual property rights.
Financial Terms
Under the agreement, Genentech will pay a USD60 million upfront payment. It is also committed to up to USD590 million in development and commercialization milestone payments, alongside a net sales-based tiered commission.
Drug Details
Androgen receptor signaling is a recognized driver of prostate cancer. JMKX00299 is designed to have therapeutic potential for patients who develop resistance to existing prostate cancer therapies, according to the press release.
Significance of the Deal
This deal marks Jemincare’s third out-license project and is by far the most significant in monetary terms. Previously, Jemincare licensed a novel non-opioid drug candidate to Finnish firm Orion Corporation for rights outside China in May this year. In November 2021, it licensed a KRAS inhibitor to Huya Biosciences for ex-China development.-Fineline Info & Tech
